Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
Biotech
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
Echo Biotech Secures Series A++ Funding for Exosomes Drug Development
Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi...
Hexin Medical Technology Raises Series A Funding for Radionuclide Therapy
Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised...
Zai Lab Reports 2022 Financial Results with Revenue Growth
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...
Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III...
BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results
BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...
3SBio Terminates Distribution Agreement with AstraZeneca for Byetta
China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK...
Eluminex Biosciences Closes $40M Series B for Ophthalmic Innovations
China-based ophthalmic biotech Eluminex Biosciences (Suzhou) Ltd has announced the closure of a Series B...
Suzhou Porton Biologics Partners with CorrGene for Cell and Gene Therapy
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has announced a strategic...
Kelun-Biotech Files for Hong Kong IPO with Goldman Sachs and CITIC Securities
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its high-end preparation subsidiary,...
BeiGene’s Tislelizumab Approved for Gastric Tumors in China
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that its programmed death-1 (PD-1) inhibitor...
SciClone Partners with Cowell Health to Enhance Cancer Treatment Accessibility
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...
Danatlas Raises Pre-Series A Funding for Synthetic Lethality Drug Development
Beijing-headquartered Danatlas, a first-in-class drug developer specializing in the synthetic lethality field, has reportedly raised...
Bio-Thera Solutions Partners with China Resource Medicine for Integrated Collaboration
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced a strategic partnership with compatriot firm China...
ConjuStar Peptide-Drug Conjugate Angel Financing
Tianjin-based ConjuStar, a peptide-drug conjugate (PDC) developer incubated by Fosun Pharma and Wuxi Apptec, has...
TransThera Biosciences Completes Series D+ Financing Round
China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing...
Zai Lab Partners with Sir Run Run Shaw Hospital for Medical Innovation Center
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced a strategic partnership agreement...
Kactus Biosystems and Levinthal Biotech Deepen Strategic Partnership
Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a...
We-Linking Raises Tens of Millions in Angel Round for Brain-Computer Interface
We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly...